Action Pharma-founder to build new biotech company out of the rubble
Founder of the biotech company Action Pharma have bought the remains of the research from the recently dispersed company, and is now teaming up with colleagues in an effort to create another biotech success.
af LEONORA BECK
Søren Nielsen founded Action Pharma at the turn of the millennium, and the research – which he was responsible for as CSO in the company – has now been bought by the American pharmaceutical giant Abbott. The biotech company’s greatest asset, the candidate drug AP214 against kidney failure, is now in the hands of Abbott.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
